Printer Friendly

APPLIED BIOSCIENCE INTERNATIONAL INC. UNITES ITS THREE MAJOR LIFE SCIENCE COMPANIES TO FORM PHARMACO-LSR AND APPOINTS DEFESCHE PRESIDENT

 ARLINGTON, Va., Jan. 18 /PRNewswire/ -- Grover C. Wrenn, president and CEO of Applied Bioscience International Inc. (NASDAQ: APBI), announced today that APBI has united its three major companies in the pharmaceutical, consumer product, and chemical contract research areas -- Pharmaco, Life Science Research (LSR) and Bio/dynamics -- into one organization.
 The organization will operate under a new company name, Pharmaco- LSR. This move makes Pharmaco-LSR the first contract research organization in the world with the ability to provide complete, global, seamless product development services to pharmaceutical, industrial, chemical and agrochemical companies. Mr. Wrenn further stated that the anticipated restructuring costs associated with the formation of Pharmaco-LSR were included in the $4 million reserve announced by APBI in December of 1992.
 Mr. Wrenn also announced that Charles L. Defesche, M.D., FCP has been appointed president of Pharmaco-LSR. Dr. Defesche has been senior vice president and CEO of Pharmaco International, Inc. since November 1990, where he oversaw the functioning of Pharmaco's European operations and affiliate companies providing a full range of clinical drug development, regulatory, statistical and data management services to the health care industry. From 1981 to 1990, Dr. Defesche was associated with Boots Pharmaceuticals, Inc. of Lincolnshire, Ill. He became executive vice president and instituted a drug development program which successfully submitted three original NDAs that recently completed the Phase I-III development of a new chemical entity for the treatment of congestive heart failure, on which the NDA was the first regulatory filing in the world. In 1980-81, Dr. Defesche was head of cardiovascular clinical research at the Bayer, Belgium, pharmaceutical division. His professional organizations, publications, seminars and speaking engagements are numerous and laudatory.
 Dr. Defesche stated, "The company has made the strategic decision to integrate after much consideration. Our market research, our instincts and our clients all told us the same thing. The market is demanding a full-service organization to handle product development to enable simultaneous worldwide product distribution. Now that we have integrated, we can give our clients what they need."
 Pharmaco, a full-service clinical research organization, merged with APBI in February of 1992, has been operating as a wholly owned subsidiary of APBI since the merger. APBI is also the parent company of Bio/dynamics and LSR, both toxicology specialists. The merger brought the companies into the same operating group, but they have maintained separate management teams and independent operations until Jan. 15 of this year. The final phase of the company's strategic plan was achieved when the operating group was restructured to integrate the talent, expertise and management of the three companies into one organization: Pharmaco-LSR.
 Pharmaco-LSR will maintain all 14 of its facilities in the United States, England, France, Germany, Belgium and Sweden, and will continue activities in Japan.
 APBI provides a broad range of inter-related services, including biological safety testing and clinical research and development through its Life Sciences Group, and assessment and management of chemical and environmental risk, agrochemical research and development, and related analytical chemistry services through its Environmental Sciences Group. These services are provided under contract to clients in the pharmaceutical, general chemical, agrochemical, and other industries worldwide.
 -0- 1/18/93
 /CONTACT: John H. Timoney, senior vice president of Applied Bioscience International Inc., 908-873-2550, or John McNamara of John McNamara Advertising, Inc., 212-509-7779, for Applied Bioscience International Inc./
 (APBI)


CO: Applied Bioscience International Inc. ST: New Jersey IN: MTC SU:

SM-CK -- NY022 -- 5828 01/18/93 10:44 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 18, 1993
Words:569
Previous Article:JOHN W. CHIERICHELLA JOINS FRIED FRANK'S WASHINGTON OFFICE
Next Article:MIDSIZED U.S. MANUFACTURERS WANT CLINTON TO PUT CAPITAL INVESTMENT, REGULATORY REFORM HIGH ON HIS AGENDA
Topics:


Related Articles
APPLIED BIOSCIENCE INTERNATIONAL MERGES WITH PHARMACO DYNAMICS RESEARCH
THREE COMPANIES UNITE TO BECOME THE WORLD'S FIRST COMPLETELY INTEGRATED CONTRACT PRODUCT DEVELOPMENT COMPANY
ZONAGEN, INC. BEGINS PHASE II CLINICAL TRIAL OF 'ON DEMAND' ORAL TREATMENT FOR MALE IMPOTENCY
APPLIED BIOSCIENCE INTERNATIONAL INC. REPORTS RESULTS
Pharmaceutical Product Development, Inc., Acquisition of Data Analysis and Research (Dar) Ltd. Completed
Pharmaceutical Product Development, Inc. Names Dr. Loren Miller Executive Director, Regulatory and Product Development
Vitra Bioscience Appoints Andrew P. Whiteley President and Chief Executive Officer.
Genaissance Pharmaceuticals Appoints Ben D. Kaplan Senior Vice President and Chief Financial Officer.
Sir Richard Sykes, Former Glaxo Wellcome Chairman, CEO and GlaxoSmithKline Chairman, Agrees to Join the Abraxis BioScience Board of Directors.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters